

In XXI century Central Nervous System (CNS) disorders in developed countries outnumber diseases in other therapeutic areas resulting in greater financial strain on healthcare and economies at large. Aging population adds to the trend with steady increase in neurodegenerative diseases and related conditions.

CNS drug development could be the riskiest research area as modern science has relatively limited understanding of precise mechanisms involved in brain diseases and target specific therapies are hard to come by.

With the awareness of selectivity challenge, ActiTarg-CNS, focuses on diverse structural variations and targets primarily three general receptor groups: serotonin, dopamine, and acetylcholine. Each receptor family in its downstream signaling pathways commands broad spectrum of neurological processes.

**Serotonin receptors:** *5-HT1-2 and 5-HT in general and related 1-D2 like*      **Dopamine receptors:** *D*

### **Acetylcholine receptors**

:

*Nicotinic acetylcholine receptors (nAChR) and Muscarinic acetylcholine receptors (mAChR)*

### **Nonpeptidic caspase inhibitors**

260 approved and experimental CNS drugs and 77 active molecules common fragments were used in computational tool training to ensure targets-relevant and at the same time highly chemically diverse selection of 3600 compounds suitable for neuropharmaceutical leads discovery.

ActiTarg-CNS 3600 is available for pooling customized subsets in required formatting and as a pre-designed collection in 10mmol concentration.

### **Related Products**

[ActiTarg-G](#) GPCR Ligands

[ActiTarg-K](#) Kinase Modulators

[ActiTarg-P](#) Protease

Inhibitors

[ctiTarg-S](#)

Serpins Inhibitors

[A](#)

[ActiTarg-I](#)

Potassium Channel Modulators

[ActiTarg-N](#)

Nuclear Receptor Ligands

[ActiTarg-](#)

[H](#)

HDAC Inhibitors